Sarepta Therapeutics, Inc. October 31, 2023 - by Joey Ramson $SRPT is down about 40% and testing the lows of the stock for 2021 and 2022 after new data was released for its gene therapy to treat Ducchenne muscular dystrophy on Monday. Share this article:
